Centron, a full-service, wholly integrated healthcare communications firm and recipient of Med Ad News Agency of the Year in 2016, announced the appointment of David Stolzer as Senior Vice President, Digital Strategy and Innovation.
Kite Pharma Inc. today highlighted a publication in the latest issue of Nature Methods that describes pre-clinical findings demonstrating that a novel serum-free, 3-dimensional cell culture technology, known as the Artificial Thymic Organoid (ATO) cell culture system, recapitulates T-cell differentiation.
Understanding the nuances behind why a physician makes a decision regarding an information source when making a clinical decision is key to learning the best way to deliver content that will prompt an engagement.
Napo Pharmaceuticals Inc. – a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas – and Jaguar Animal Health Inc. – an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals and high value horses – announced today that they have entered into a definitive merger agreement by unanimous approval by the boards of directors of both companies.
The U.S. FDA granted full approval for Tagrisso (osimertinib) 80-mg once-daily tablets for treating metastatic EGFR T790M mutation-positive NSCLC.
As biologic medications administered through prefilled syringes continue to supplement and enter new therapeutic areas, more and more patients will need to embark on a learning curve that is possibly unlike any they have experienced prior.
Espero Pharmaceuticals – a commercial-stage cardiovascular pharma company – and Armetheon – a late-clinical stage pharma company developing innovative novel drugs addressing major unmet needs in cardiovascular diseases – plan to merge.
Heartbeat announced that its founder Bill Drummy has stepped down as CEO after 18 years of running the perennially successful healthcare marketing agency.
Pfizer Inc. today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that Trumenba (Meningococcal Group B Vaccine) be granted marketing authorization in the European Union for active immunization of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB).
Habit and red tape are not sufficient excuses for life sciences organizations to keep doing things the way they always have.
